SECTION 06 / FREQUENT QUESTIONS
CJC-1295 FAQ: the questions readers actually ask, answered from the record
Direct answers, cited where the claim is quantitative. Where the literature is silent, the answer says so.
What CJC-1295 is
This page is the index of the questions readers bring to CJC-1295, answered directly from the published record. Where a claim is quantitative, it is cited; where the literature is silent, the answer says so rather than guessing.
What is CJC-1295?
CJC-1295 is a synthetic long-acting analog of growth-hormone-releasing hormone, built on hGRF(1-29) with four protease-resistant substitutions [2]. The DAC variant adds covalent serum-albumin conjugation for a multi-day half-life [1]; it is an unapproved research chemical.
What does CJC-1295 do?
In research, it binds the GHRH receptor on pituitary somatotrophs and stimulates pulsatile growth-hormone release, which raises hepatic IGF-1 [2]. Human pharmacokinetic studies showed dose-dependent GH and IGF-1 elevation lasting days [1].
Is CJC-1295 a steroid?
No. CJC-1295 is a peptide GHRH analog that stimulates the body's own growth-hormone release; it is not an anabolic-androgenic steroid and acts on the GHRH receptor, not the androgen receptor [2].
What is CJC-1295 with DAC?
DAC ("Drug Affinity Complex") is a maleimide linker that covalently binds the peptide to circulating serum albumin, extending the plasma half-life toward 5.8-8.1 days [1][2]. "CJC-1295 with DAC" is the long-acting, albumin-conjugated form.
What is CJC-1295 DAC?
The albumin-conjugated, long-acting variant of CJC-1295. The DAC chemistry was identified in the discovery work that screened hGRF(1-29)-albumin bioconjugates and named CJC-1295 as the lead long-lasting GHRH analog [2]. See CJC-1295 DAC vs no-DAC for the full distinction.
What is CJC-1295 ipamorelin?
A frequently studied pairing of CJC-1295 (a GHRH analog) with ipamorelin (a selective GHRP/secretagogue). The two engage different receptors — the GHRH receptor and the ghrelin/GHS receptor — which is the basis for combining them in growth-hormone-axis research [10].
Safety and side effects
Is CJC-1295 safe?
Safety in humans is not established: published data are limited to short early-phase pharmacokinetic studies [1], and theoretical concerns include fluid retention, effects on insulin sensitivity, IGF-1/cancer-risk epidemiology, and immunogenicity flagged in 2024 FDA briefing materials. It is not approved for human use.
Are CJC-1295 peptides safe?
Human safety is not established. The published evidence is limited to early pharmacokinetic studies [1], and sustained GH/IGF-1 elevation raises theoretical concerns — fluid retention, insulin sensitivity, IGF-1/cancer epidemiology, immunogenicity. It is handled as a research chemical only.
What are the side effects of CJC-1295?
Reported and theoretical concerns from GH-axis stimulation include fluid retention and edema, effects on insulin sensitivity, and the IGF-1/cancer-risk epidemiology; FDA briefing materials also cited immunogenicity. Controlled long-term safety data in healthy adults do not exist [1].
Does CJC affect testosterone?
CJC-1295 acts on the GH/IGF-1 axis, not the gonadal axis, and the published literature does not document a direct testosterone effect [2]. Claims that it raises or lowers testosterone are not supported by the peer-reviewed CJC-1295 data.
Doses, handling, and the ipamorelin pairing
How much CJC-1295 should I take?
Human PK studies used single subcutaneous doses of 30, 60 or 90 micrograms per kilogram [1][3]. Community fixed-dose protocols are not derived from controlled human trials, and no human dose is established for any use [1]. This describes what was studied, not a recommendation.
How much CJC-1295 DAC should I take?
Controlled human pharmacokinetic work used 30-90 microgram-per-kilogram single subcutaneous doses of the DAC variant, with IGF-1 elevation persisting up to 28 days after multiple doses [1]. No validated human dosing regimen exists; the multi-day half-life distinguishes DAC handling from the short-acting no-DAC form.
How much CJC-1295 / ipamorelin should I take?
The GHRH-analog-plus-GHRP pairing is studied mechanistically — the two act on distinct receptors and synergize [10] — but no controlled human dosing regimen for the combination is established, and circulating fixed-dose protocols are not trial-derived [1].
How to reconstitute CJC-1295?
In research handling the lyophilized peptide is reconstituted with bacteriostatic water and refrigerated; oral bioavailability is negligible [1]. This describes laboratory handling only, not a human-use protocol.
Where to inject CJC-1295?
The route studied in humans and animals is subcutaneous injection, with intravenous used in early GRF(1-29) pharmacokinetic work [1][2]. Site-specific injection guidance is outside the research literature and is not provided here.
Efficacy and what to expect
Does CJC-1295 and ipamorelin work?
The mechanistic rationale is sound — GHRH analogs and GHRPs synergize to raise GH more than either alone, and ipamorelin is a selective GH secretagogue [10]. But there are no controlled efficacy trials of the CJC-1295/ipamorelin combination in healthy adults [1].
What to expect when taking CJC-1295?
In the research setting, CJC-1295 produced dose-dependent, multi-day elevation of GH and IGF-1 while preserving GH pulsatility [1][3]. Outcomes beyond those pharmacokinetic and endocrine readouts are not established in controlled human trials, and nothing here is a use recommendation.
Are peptides safer than TRT?
The two act on different axes — testosterone-replacement therapy supplies androgen directly, while CJC-1295 stimulates the GH/IGF-1 axis. There is no head-to-head safety trial; CJC-1295 itself has only early-phase human pharmacokinetic data [1], so "safer" is not established in the literature.
How do anabolic steroids compare to peptides like CJC-1295 and ipamorelin for muscle building and health risks over 50?
Anabolic steroids act on the androgen receptor; CJC-1295 (a GHRH analog) and ipamorelin (a GHRP) stimulate endogenous GH and IGF-1 [2][10]. The published CJC-1295 evidence in adults is limited to short-term pharmacokinetic studies [1], so comparative muscle-building efficacy and long-term risk — at any age, including over 50 — are not characterized in controlled trials.
How does CJC-1295 compare to tesamorelin, the FDA-approved GHRH analog?
Tesamorelin is an FDA-approved GHRH analog with Phase 3 RCT data showing reduced visceral and hepatic fat in HIV-associated lipodystrophy [7][8]. CJC-1295 is an unapproved research chemical whose human evidence is limited to early pharmacokinetic studies [1]; tesamorelin is the closest approved benchmark, not an equivalent. The full comparison is on CJC-1295 vs tesamorelin.
Which is better, MK-677 or CJC-1295 / ipamorelin?
MK-677 (ibutamoren) is an orally active ghrelin-receptor secretagogue; CJC-1295 is an injectable GHRH analog often paired with the GHRP ipamorelin [10]. They engage different receptors and no controlled head-to-head exists, so "better" depends on undefined endpoints rather than trial data [1].
Regulatory and WADA status
Is CJC-1295 FDA approved?
No. CJC-1295 is not approved by the FDA or any major regulator for human use. It was reviewed at the 2024 FDA Pharmacy Compounding Advisory Committee and not recommended for the list of substances pharmacies may compound.
CJC-1295 is also prohibited at all times in sport under Section S2 (peptide hormones, growth factors and mimetics) of the WADA Prohibited List, and is banned by bodies such as the NCAA. Detection assays based on LC-MS/MS and immuno-PCR are well established [6][13], and the compound has been identified analytically in a seized preparation [6]. For the closest approved analog, see CJC-1295 vs tesamorelin.